Retatrutide 20mg

Retatrutide 3-GLP (20mg) | Triple Receptor Precision

Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, offering researchers a uniquely powerful tool for studying multi-pathway metabolic modulation. Where single-receptor peptides hit one lever, Retatrutide engages the full axis.

Formulated to the Transduction Standard:

• Triple-Receptor Activity: Simultaneous GLP-1, GIP, and glucagon receptor agonism in a single compound — ideal for comparative and mechanistic metabolic research.

• 99%+ Verified Purity: Every batch undergoes independent third-party HPLC analysis. Results are published in our open COA Library — no black-box sourcing, ever.

• Protocol-Ready: Pair with our Retatrutide Handling Protocol for reconstitution guidance, storage parameters, and dosing reference data.

COMPLIANCE NOTICE: This compound is provided strictly for in vitro laboratory research use only. It is not an FDA-approved drug and is not intended for human consumption, clinical administration, or therapeutic use of any kind.